July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Exosomes Derived from Mesenchymal Stem/stromal Cells Protect the Ocular Surface in the mouse model of Sjögren’s Syndrome
Author Affiliations & Notes
  • Min Joung Lee
    Ophthalmology, Hallym University Sacred Heart Hospital, Anyang, Gyeonggi-do, Korea (the Republic of)
  • Jin Suk Ryu
    Laboratory of Ocular Regenerative Medicine and Immunology, Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea (the Republic of)
  • Ryang Hwa Lee
    Institute for Regenerative Medicine, Texas A&M Health Science Center College of Medicine at Scott and White, Temple, Texas, United States
  • Joo Youn Oh
    Ophthalmology, Seoul National University Hospital, Seoul, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Min Joung Lee, None; Jin Suk Ryu, None; Ryang Hwa Lee, None; Joo Youn Oh, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3297. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Min Joung Lee, Jin Suk Ryu, Ryang Hwa Lee, Joo Youn Oh; Exosomes Derived from Mesenchymal Stem/stromal Cells Protect the Ocular Surface in the mouse model of Sjögren’s Syndrome. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3297.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Inflammation and impaired secretion of lacrimal glands are hallmarks of Sjogren’s syndrome, and promote dryness and inflammation of ocular surface. Recently, extracellular vesicles (EVs) derived from mesenchymal stem/stromal cells (MSCs) were reported to have most of anti-inflammatory activity of MSCs. This study tested the therapeutic potential of MSCs-derived EVs in mouse model of primary Sjögren’s syndrome.

Methods : In this study, we used 12-week-old NOD.B10.H2b mice, a model for primary Sjögren’s syndrome. Either phosphate buffered saline (PBS) or EVs were injected into intraorbital and extraorbital lacrimal glands. One week later, tear production was measured by phenol red thread test, and the corneal surface was observed for epithelial defects. Infiltration of immune cells in lacrimal glands was analyzed by immunohistochemistry. Also, the number of goblet cells was evaluated in the forniceal conjunctiva.

Results : Injection of EVs into lacrimal glands significantly improved tear production in NOD mice (5.10 ± 0.32 mm), compared to controls with PBS administration (3.19 ± 0.22 mm, p=0.0001). Also, corneal epithelial defects were significantly reduced (p=0.0018). Inflammatory foci of intraorbital lacrimal glands were significantly reduced in EVs-injected mice (51.2 ± 21.7) than controls (72.8 ± 14.2, p=0.02). The number of conjunctival goblet cells was not different between two groups (p=0.617).

Conclusions : We demonstrated injection of EVs into lacrimal glands promoted tear production and clinically protected the corneal surface in NOD mice. The results suggested that EVs repressed the inflammation in the lacrimal glands.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×